Effect of Remimazolam Supplementation on Propofol Requirements During Hysteroscopy: A Double-Blind, Dose-Response Study
Authors' conclusion
For women undergoing hysteroscopic procedures, remimazolam at doses from 0.1 to 0.2 mg·kg -1 reduced the EC 50 of propofol inhibiting response to cervical dilation and the total propofol requirement.
Study context
- Population
- Patients scheduled for hysteroscopy
- Participants
- 150 patients
- Comparison
- Remimazolam 0.05, 0.1, 0.15 or 0.2 vs 0 mg·kg −1 before TCI propofol
- Primary endpoint
- EC 50 of effect-site propofol concentration (Ce prop) suppressing response to cervical dilation
Methodological detailsdouble-blind, dose-response, up-down sequential analysis
- Double-blind
- Dose-response
- Up-down sequential analysis
Primary result
As reported in the abstract
EC 50 of propofol for suppressing response to cervical dilation
Decrease in EC 50
43.3 %
95% CI 41.3%–45.5%
0.1 mg·kg −1 · 0.1, 0.15 and 0.2 lower than 0 and 0.05; all P < .005
Decrease in EC 50
50.3 %
95% CI 48.0%–52.8%
0.15 mg·kg −1
Decrease in EC 50
61.2 %
95% CI 58.7%–63.8%
0.2 mg·kg −1
Further findings
Propofol consumption
- Propofol consumption: 0.1, 0.15 and 0.2 vs 0: all were P < .005
Time to anesthesia emergence
- Did not differ significantly among the 5 groups
Original publication
Effect of Remimazolam Supplementation on Propofol Requirements During Hysteroscopy: A Double-Blind, Dose-Response Study. Anesth Analg. Published 27 February 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →